Kohlenberg, AnkeSvartström, OlovApfalter, PetraHartl, RainerBogaerts, PierreHuang, Te-DinChudejova, KaterinaMalisova, LuciaEisfeld, JessicaSandfort, MircoHammerum, Anette M.Roer, LouiseRäisänen, KatiDortet, LaurentBonnin, Rémy A.Tóth, ÁkosTóth, KingaClarke, ChristinaCormican, MartinGriškevičius, AlgirdasKhonyongwa, KirstinMeo, MarieNiedre-Otomere, BaibaVangravs, ReinisHendrickx, Antoni PaNotermans, Daan WSamuelsen, ØrjanCaniça, ManuelaManageiro, VeraMüller, VilhelmMäkitalo, BarbroKramar, UrškaPirs, MatejaPalm, DanielMonnet, Dominique L.Alm, ErikLinkevicius, Marius2025-02-272025-02-272024-11Euro Surveill. 2024 Nov;29(47):2400727. doi: 10.2807/1560-7917.ES.2024.29.47.24007271560-7917http://hdl.handle.net/10400.18/10396Analysis of 594 isolates of sequence type (ST)131 and its single locus variants carrying carbapenemase genes from 17 European Union/European Economic Area countries revealed acquisition of 18 carbapenemase variants, mainly in ST131 clades A and C. Most frequent were (n = 230) and (n = 224), detected in 14 and 12 countries, respectively. Isolates carrying have increased rapidly since 2021. The increasing detection of carbapenemase genes in the high-risk lineage ST131 is a public health concern.enCarbapenem-resistant EnterobacteralesEscherichia coliAntibioticsAntimicrobial ResistanceCarbapenemaseCross-border SpreadSurveillanceWhole Genome SequencingResistência aos Antimicrobianosjournal article10.2807/1560-7917.ES.2024.29.47.240072739574387